Rates of serious infections and malignancies among rheumatoid arthritis patients receiving either TNF blocker or rituximab therapy

Aaltonen K. J.; Joensuu J. T.; Virkki L.; Sokka T.; Relas H.; Valleala H.; Rantalaiho V.; Pirila L.; Puolakka K.; Uusitalo T.; Blom M.; Konttinen Y. T.; Nordstrom D.

首页> 外文期刊>Scandinavian journal of rheumatology >Rates of serious infections and malignancies among rheumatoid arthritis patients receiving either TNF blocker or rituximab therapy

【24h】

Rates of serious infections and malignancies among rheumatoid arthritis patients receiving either TNF blocker or rituximab therapy

机译：接受TNF阻断剂或利妥昔单抗治疗的类风湿关节炎患者中严重感染和恶性肿瘤的发生率

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Scandinavian journal of rheumatology》 |2014年第5期|共1页
作者
Aaltonen K. J.; Joensuu J. T.; Virkki L.; Sokka T.; Relas H.; Valleala H.; Rantalaiho V.; Pirila L.; Puolakka K.; Uusitalo T.; Blom M.; Konttinen Y. T.; Nordstrom D.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类免疫性疾病;
关键词

相似文献

外文文献
中文文献
专利

1. Rates of serious infections and malignancies among rheumatoid arthritis patients receiving either TNF blocker or rituximab therapy [J] . Aaltonen K. J., Joensuu J. T., Virkki L., Scandinavian journal of rheumatology . 2014,第5期

机译：接受TNF阻断剂或利妥昔单抗治疗的类风湿关节炎患者中严重感染和恶性肿瘤的发生率
2. Rituximab is more effective than second anti-TNF therapy in rheumatoid arthritis patients and previous TNFα blocker failure [J] . Joern Kekow, Ulf Mueller-Ladner, Hendrik Schulze-Koops Biologics: Targets and Therapy . 2012,第6期

机译：对于类风湿关节炎患者和先前的TNFα阻滞剂失败，利妥昔单抗比第二种抗TNF治疗更有效
3. Serious infection risk after 1 year between patients with rheumatoid arthritis treated with rituximab or with a second TNFi after initial TNFi failure: results from The British Society for Rheumatology Biologics Register for Rheumatoid Arthritis [J] . Silva-Fernandez Lucia, De Cock Diederik, Lunt Mark, Rheumatology . 2018,第9期

机译：在初始TNFI失败后，用Rituximab治疗的类风湿性关节炎或患有第二次TNFI患者的严重感染风险
4. Insulin resistance in rheumatoid arthritis: the impact of the anti-TNF-α therapy [C] . Miguel A. Gonzalez-Gay, Carlos Gonzalez-Juanatey, Tomas R. Vazquez-Rodriguez, International Conference on the Neuroendocrine Immune Basis of the Rheumatic Diseases . 2010

机译：类风湿性关节炎中胰岛素抵抗力：抗TNF-α治疗的影响
5. Vaccinia virus complement control protein ameliorates collagen induced arthritis: Potential implications for therapy of rheumatoid arthritis. [D] . Jha, Purushottam. 2003

机译：牛痘病毒补体控制蛋白可改善胶原蛋白诱发的关节炎：类风湿关节炎的治疗潜力。
6. Rituximab is more effective than second anti-TNF therapy in rheumatoid arthritis patients and previous TNFα blocker failure [O] . Joern Kekow, Ulf Mueller-Ladner, Hendrik Schulze-Koops 2012

机译：在类风湿关节炎患者和先前的TNFα阻滞剂失败的患者中利妥昔单抗比第二种抗TNF治疗更有效
7. The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis [O] . Silva-Fernández L, Lunt M, Kearsley-Fleet L, 2016

机译：接受TNF抑制剂或利妥昔单抗的类风湿性关节炎和既往恶性肿瘤患者的癌症发病率：英国风湿病学会生物制剂登记 - 类风湿性关节炎的结果

Rates of serious infections and malignancies among rheumatoid arthritis patients receiving either TNF blocker or rituximab therapy

著录项

相似文献

相关主题

期刊订阅